Abstract
Methods Subjects 5 years and older with ARC with/without asthma received once-daily 2800 BAU sublingual grass AIT (oral lyophilisate, Phleum pratense, 75,000 SQ-T, ~15μg Phl p5) or placebo starting approximately 16 weeks before and continuing throughout the 2009 grass pollen season (GPS). Subjects used daily e-diaries to record ARC symptoms and use of symptomatic medications from randomization through study end (approximately 24 weeks). The primary efficacy endpoint comprised the average total combined daily symptom and medication score (TCS) during the entire GPS. Secondary endpoints included average daily symptom score (DSS) and average daily medication score (DMS). Safety was assessed by monitoring adverse events (AEs).
Highlights
The effect of Timothy grass allergy immunotherapy tablet (AIT) treatment on a Canadian subpopulation was assessed post-hoc using data from 2 randomized, double-blind, trials designed to evaluate grass AIT in North American subjects
Safety was assessed by monitoring adverse events (AEs)
AIT-treated subjects showed reductions, vs placebo, of 38% (P=.016) for entire and 45% (P=.005) for peak seasons in TCS; of 38% (P=.013) for entire and 40% (P=.008) for peak seasons in daily symptom score (DSS); and of 39% for entire (P=.238) and 60% (P=.005) for peak seasons in daily medication score (DMS)
Summary
Efficacy of Timothy grass allergy immunotherapy tablet (AIT) treatment in Canadian children and adults with grass pollen-induced allergic rhinoconjunctivitis (ARC). Jacques Hebert1*, Hendrik Nolte, Jennifer Maloney, Michael Blaiss, Harold S Nelson. From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2011 Quebec, Canada. From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2011 Quebec, Canada. 20-23 October 2011
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
